• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血栓性血小板减少性紫癜(TTP)的诊断和临床管理:TTP 加泰罗尼亚小组的共识声明。

Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group.

机构信息

Hemotherapy, Banc de Sang i Teixits, Càtedra UAB de Medicina Transfusional i Teràpia Cel·lular i Tissular, Hospital Universitary of Bellvitge, L'Hospitalet de Llobregat, Catalonia, Spain.

Internal Medicine, Hospital Universitary of Bellvitge, L'Hospitalet de Llobregat, Catalonia, Spain.

出版信息

Blood Transfus. 2024 Mar;22(2):176-184. doi: 10.2450/BloodTransfus.522. Epub 2023 Sep 4.

DOI:10.2450/BloodTransfus.522
PMID:37677097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10920070/
Abstract

Thrombotic thrombocytopenic purpura (TTP) is a low prevalence disease characterized by severe deficiency of the enzyme ADAMTS13, leading to the development of thrombotic microangiopathy (TMA) and often resulting in severe organ disfunction. TTP is an extremely serious condition and, therefore, timely and appropriate treatment is critical to prevent life-threatening complications.Over the past 25 years, significant advances in the understanding of the pathophysiology of immune TTP have led to the development of readily available techniques for measuring ADAMTS13 levels, as well as new drugs that are particularly effective in the acute phase and in preventing relapses. These developments have improved the course of the disease.Given the complexity of the disease and its various clinical and laboratory manifestations, early diagnosis and treatment can be challenging.To address this challenge, a group of experienced professionals from the Catalan TTP group have developed this consensus statement to standardize terminology, diagnosis, treatment and follow up for immune TTP, based on currently available scientific evidence in the field. This guidance document aims to provide healthcare professionals with a comprehensive tool to make more accurate and timely diagnosis of TTP and improve patient outcomes.

摘要

血栓性血小板减少性紫癜(TTP)是一种低发病率疾病,其特征为 ADAMTS13 酶严重缺乏,导致血栓性微血管病(TMA)的发生,并常导致严重的器官功能障碍。TTP 是一种极其严重的病症,因此,及时和适当的治疗对于预防危及生命的并发症至关重要。在过去的 25 年中,人们对免疫性 TTP 的病理生理学有了更深入的了解,这导致了易于测量 ADAMTS13 水平的技术以及新药物的发展,这些药物在急性阶段和预防复发方面特别有效。这些进展改善了疾病的进程。鉴于疾病的复杂性及其各种临床和实验室表现,早期诊断和治疗可能具有挑战性。为了应对这一挑战,一个来自加泰罗尼亚 TTP 小组的经验丰富的专业人员小组根据该领域目前可用的科学证据,制定了本共识声明,以规范免疫性 TTP 的术语、诊断、治疗和随访。本指导文件旨在为医疗保健专业人员提供一种全面的工具,以便更准确和及时地诊断 TTP 并改善患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/10920070/d2c5298b2d41/BLT-22-176_g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/10920070/d2c5298b2d41/BLT-22-176_g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f606/10920070/d2c5298b2d41/BLT-22-176_g001.jpg

相似文献

1
Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group.血栓性血小板减少性紫癜(TTP)的诊断和临床管理:TTP 加泰罗尼亚小组的共识声明。
Blood Transfus. 2024 Mar;22(2):176-184. doi: 10.2450/BloodTransfus.522. Epub 2023 Sep 4.
2
Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.利妥昔单抗治疗与免疫介导的严重ADAMTS13缺乏相关的难治性和/或复发性血栓性血小板减少性紫癜:4例报告及文献系统综述
Eur J Haematol. 2009 Oct;83(4):365-72. doi: 10.1111/j.1600-0609.2009.01292.x. Epub 2009 Jun 8.
3
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明:2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.
4
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).噻氯匹定和氯吡格雷相关的血栓性血小板减少性紫癜(TTP):临床、实验室、流行病学及药物警戒研究结果综述(1989 - 2008年)
Kidney Int Suppl. 2009 Feb(112):S20-4. doi: 10.1038/ki.2008.613.
5
Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases.被误诊为血栓性血小板减少性紫癜的播散性恶性肿瘤:10例报告及已发表病例的系统评价
Oncologist. 2007 Jan;12(1):11-9. doi: 10.1634/theoncologist.12-1-11.
6
[Management of congenital thrombotic thrombocytopenic purpura in the era of recombinant ADAMTS13 protein: Recommendations from the Reference Center for Thrombotic Microangiopathies (CNR-MAT)].[重组ADAMTS13蛋白时代先天性血栓性血小板减少性紫癜的管理:血栓性微血管病参考中心(CNR-MAT)的建议]
Rev Med Interne. 2025 Jul;46(7):397-407. doi: 10.1016/j.revmed.2024.11.004. Epub 2024 Nov 21.
7
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.评估慢性阻塞性肺疾病干预措施的比较效果:面向临床医生的网状Meta分析教程
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
8
Diagnosis and management of dental caries throughout life.一生当中龋齿的诊断与管理。
NIH Consens Statement. 2001;18(1):1-23.
9
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.溶血尿毒综合征和血栓性血小板减少性紫癜的干预措施。
Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD003595. doi: 10.1002/14651858.CD003595.pub2.
10
HIV-associated thrombotic thrombocytopenic purpura (HIV-TTP): A practical guide and review of the literature.HIV 相关性血栓性血小板减少性紫癜(HIV-TTP):实用指南及文献复习。
HIV Med. 2022 Nov;23(10):1033-1040. doi: 10.1111/hiv.13305. Epub 2022 Apr 3.

引用本文的文献

1
Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura.实验室生物标志物在血栓性血小板减少性紫癜死亡风险分层中的预后价值
Ann Hematol. 2025 Aug 30. doi: 10.1007/s00277-025-06584-8.
2
The third form of thrombotic thrombocytopenic purpura shows up again: what is it, does it even exist, how to find out? Comment on "Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism" and on "The different faces of thrombotic thrombocytopenic purpura".血栓性血小板减少性紫癜的第三种形式再次出现:它是什么,是否真的存在,如何查明?对《无可检测的抗ADAMTS13抗体的获得性血栓性血小板减少性紫癜:一种可能的潜在自身免疫机制》及《血栓性血小板减少性紫癜的不同表现》的评论
Haematologica. 2025 Jun 1;110(6):1445-1448. doi: 10.3324/haematol.2025.287535. Epub 2025 Feb 27.
3

本文引用的文献

1
Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura.利妥昔单抗治疗免疫介导的血栓性血小板减少性紫癜
Blood Transfus. 2023 Sep;21(5):369-374. doi: 10.2450/BloodTransfus.503. Epub 2023 Mar 17.
2
Validation of PLASMIC score in a cohort of patients with suspected thrombotic microangiopathy in an academic medical centre.验证 PLASMIC 评分在学术医疗中心疑似血栓性微血管病患者队列中的应用。
Blood Transfus. 2023 Jul;21(4):345-349. doi: 10.2450/2022.0082-22. Epub 2022 Aug 9.
3
Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura.
Types of plasma exchange solution in the new scenario of thrombotic thrombocytopenic purpura treatment.血栓性血小板减少性紫癜治疗新场景下的血浆置换溶液类型。
Blood Transfus. 2024 May;22(3):275-276. doi: 10.2450/BloodTransfus.744. Epub 2024 Mar 4.
4
Thrombotic thrombocytopenic purpura: optimal management of plasma exchange, platelets and infection prevention.血栓性血小板减少性紫癜:血浆置换、血小板及感染预防的最佳管理
Blood Transfus. 2024 May;22(3):273-274. doi: 10.2450/BloodTransfus.710. Epub 2024 Mar 4.
血栓性血小板减少性紫癜患者的诊断和治疗建议。
Med Clin (Barc). 2022 Jun 24;158(12):630.e1-630.e14. doi: 10.1016/j.medcli.2021.03.040. Epub 2021 Jul 12.
4
Redefining outcomes in immune TTP: an international working group consensus report.重新定义免疫性血栓性血小板减少性紫癜的结局:国际工作组共识报告。
Blood. 2021 Apr 8;137(14):1855-1861. doi: 10.1182/blood.2020009150.
5
PLASMIC score: Not intended to replace but rather to prompt the ADAMTS13 testing.血浆评分:并非用于取代而是用于促使进行ADAMTS13检测。
Transfusion. 2020 Dec;60(12):3070-3072. doi: 10.1111/trf.16105.
6
Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?所有免疫介导的血栓性血小板减少性紫癜患者都应该接受卡普西单抗治疗吗?
J Thromb Haemost. 2021 Jan;19(1):58-67. doi: 10.1111/jth.15194. Epub 2020 Dec 17.
7
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.卡泊单抗、免疫抑制和血浆置换联合治疗方案可预防免疫介导的血栓性血小板减少性紫癜的不良结局。
Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021.
8
Real-world experience with caplacizumab in the management of acute TTP.卡普拉昔单抗治疗急性 TTP 的真实世界经验。
Blood. 2021 Apr 1;137(13):1731-1740. doi: 10.1182/blood.2020007599.
9
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.真实世界数据证实了卡普拉珠单抗在获得性血栓性血小板减少性紫癜中的疗效。
Blood Adv. 2020 Jul 14;4(13):3085-3092. doi: 10.1182/bloodadvances.2020001973.
10
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).卡泊珠单抗治疗获得性血栓性血小板减少性紫癜(大力神试验)。
Transfus Med. 2019 Jun;29(3):146-148. doi: 10.1111/tme.12615.